Immunohistochemical Expression of NQO1 in Premalignant Lesions and Squamous Cell Carcinoma of Cervix and its Correlation with Histopatholigic Factors

Document Type : Original Article

Authors

1 Professor, Department of Pathology, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.

2 Associate Professor, Department of Pathology, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.

3 Assistant Professor, Department of Molecular Medicine, Cancer Molecular Pathology Research Center, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.

4 Pathologist, Non-Communicable Diseases Research Center, Sabzevar University of Medical Sciences, Sabzevar, Iran.

Abstract

Introduction: Cervical cancer is one of the most important malignancies in women which has a unique progression due to premalignant lesions. The present study was performed with aim to evaluate the expression of NQO1 protein in patients with premalignant cervical lesions and squamous cell carcinoma (SCC) of the cervix and its comparison with non-dysplastic tissues.
Methods: In this cross-sectional study, paraffin-embedded blocks of patients with cervical SCC and different degrees of dysplasia and non-dysplastic tissue during 2018 to 2020 were selected as the control group from the pathology ward of Mashhad Ghaem Hospital to assess NQO1 expression by immunohistochemistry with mouse monoclonal antibody against human NQO1. Demographic data, clinicopathologic features, and survival data were assessed. Data were analyzed by SPSS (version 22) and Chi-square test, Fisher's exact test, analysis of variance, Tukey post-hoc test and log rank test. P<0.05 was considered statistically significant.
Results: In this study, 152 subjects including 31 patients with cervical SCC, 91 with different degrees of dysplasia and 30 non-dysplastic tissue were evaluated for NQO1 protein expression. Increased expression of NQO1 protein in SCC, CIN3, CIN2, CIN1 and healthy patients was 96.8%, 96.7%, 73.3%, 6.5% and 3.3%, respectively (p <0.0001). No significant correlation was found between NQO1 protein expression with tumor type (p=0.99), lymph node involvement (p=0.33), and tumor grade (p=0.40).
Conclusion: The expression of NQO1 protein in lesions with severe dysplasia was more than moderate dysplasia and in lesions with moderate dysplasia was more than mild dysplastic lesions, indicating the possible role of NQO1 protein expression changes in progression of cancer and increased severity of these lesions.

Keywords

References

  1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: a cancer journal for clinicians 2018; 68(6):394-424.
  2. Ross D, Kepa JK, Winski SL, Beall HD, Anwar A, Siegel D. NAD (P) H: quinone oxidoreductase 1 (NQO1): chemoprotection, bioactivation, gene regulation and genetic polymorphisms. Chemico-biological interactions 2000; 129(1-2):77-97.
  3. Srijiwangsa P, Na-Bangchang K. Roles of NAD (P) H-quinone oxidoreductase 1 (NQO1) on cancer progression and chemoresistance. J. Clin. Exp. Oncol 2017; 6(4):1-6.
  4. Siegel D, Gustafson DL, Dehn DL, Han JY, Boonchoong P, Berliner LJ, et al. NAD (P) H: quinone oxidoreductase 1: role as a superoxide scavenger. Molecular pharmacology 2004; 65(5):1238-47.
  5. Cui X, Li L, Yan G, Meng K, Lin Z, Nan Y, et al. High expression of NQO1 is associated with poor prognosis in serous ovarian carcinoma. BMC cancer 2015; 15(1):1-8.
  6. Ma Y, Kong J, Yan G, Ren X, Jin D, Jin T, et al. NQO1 overexpression is associated with poor prognosis in squamous cell carcinoma of the uterine cervix. BMC cancer 2014; 14(1):1-9.
  7. Cui X, Jin T, Wang X, Jin G, Li Z, Lin L. NAD (P) H: quinone oxidoreductase-1 overexpression predicts poor prognosis in small cell lung cancer. Oncology Reports 2014; 32(6):2589-95.
  8. Buranrat B, Chau-in S, Prawan A, Puapairoj A, Zeekpudsa P, Kukongviriyapan V. NQO1 expression correlates with cholangiocarcinoma prognosis. Asian Pac J Cancer Prev 2012; 13(Suppl):131-6.
  9. Hu X, Zhang Z, Ma D, Huettner PC, Massad LS, Nguyen L, et al. TP53, MDM2, NQO1, and Susceptibility to Cervical CancerTP53, MDM2, NQO1, and Cervical Cancer Susceptibility. Cancer epidemiology, biomarkers & prevention 2010; 19(3):755-61.
  10. Javadinia SA, Shahidsales S, Fanipakdel A, Joudi‐Mashhad M, Mehramiz M, Talebian S, et al. Therapeutic potential of targeting the Wnt/β‐catenin pathway in the treatment of pancreatic cancer. Journal of Cellular Biochemistry 2019; 120(5):6833-40.
  11. Javadinia SA, Shahidsales S, Fanipakdel A, Mostafapour A, Joudi-Mashhad M, Ferns GA, et al. The esophageal cancer and the PI3K/AKT/mTOR signaling regulatory microRNAs: a novel marker for prognosis, and a possible target for immunotherapy. Current Pharmaceutical Design 2018; 24(39):4646-51.
  12. Shu KX, Li B, Wu LX. The p53 network: p53 and its downstream genes. Colloids and Surfaces B: Biointerfaces 2007; 55(1):10-8.
  13. Glorieux C, Sandoval JM, Dejeans N, Ameye G, Poirel HA, Verrax J, et al. Overexpression of NAD (P) H: quinone oxidoreductase 1 (NQO1) and genomic gain of the NQO1 locus modulates breast cancer cell sensitivity to quinones. Life sciences 2016; 145:57-65.
  14. Lin L, Qin Y, Jin T, Liu S, Zhang S, Shen X, et al. Significance of NQO1 overexpression for prognostic evaluation of gastric adenocarcinoma. Experimental and Molecular Pathology 2014; 96(2):200-5.
  15. Yang Y, Zhang Y, Wu Q, Cui X, Lin Z, Liu S, et al. Clinical implications of high NQO1 expression in breast cancers. Journal of Experimental & Clinical Cancer Research 2014; 33(1):1-9.
  16. Yang Y, Jin T, Liu S, Chen L, Lin L, Han H, et al. Prognostic significance of NADPH quinine oxidoreductase 1 overexpression in head and neck squamous cell carcinoma. Zhonghua Bing li xue za zhi= Chinese Journal of Pathology 2014; 43(7):463-7.
  17. Ji M, Jin A, Sun J, Cui X, Yang Y, Chen L, et al. Clinicopathological implications of NQO1 overexpression in the prognosis of pancreatic adenocarcinoma. Oncology Letters 2017; 13(5):2996-3002.
  18. NQO1: UROTHELIAL CANCER - Interactive survival scatter ploti & Survival analysisi. Knut & Alice Wallenberg foundation; 2019. Available from: https://www.proteinatlas.org/ENSG00000181019-NQO1/pathology/urothelial+cancer#ihc.
  19. Uhlen M, Zhang C, Lee S, Sjöstedt E, Fagerberg L, Bidkhori G, et al. A pathology atlas of the human cancer transcriptome. Science 2017; 357(6352):eaan2507.
  20. Cullen JJ, Hinkhouse MM, Grady M, Gaut AW, Liu J, Zhang YP, et al. Dicumarol inhibition of NADPH: quinone oxidoreductase induces growth inhibition of pancreatic cancer via a superoxide-mediated mechanism. Cancer research 2003; 63(17):5513-20.
  21. Ahn KS, Sethi G, Jain AK, Jaiswal AK, Aggarwal BB. Genetic deletion of NAD (P) H: quinone oxidoreductase 1 abrogates activation of nuclear factor-κB, IκBα kinase, c-Jun N-terminal kinase, Akt, p38, and p44/42 mitogen-activated protein kinases and potentiates apoptosis. Journal of Biological Chemistry 2006; 281(29):19798-808.
  22. Kim JH, Cho SH, Hong YC, Kim H, Lee KY, Choe KH, et al. P2-016: Interactive effect of smoking and NQO1 for lung cancer risk. Journal of Thoracic Oncology 2007; 2(8):S488.
  23. Fagerholm R, Hofstetter B, Tommiska J, Aaltonen K, Vrtel R, Syrjäkoski K, et al. NAD (P) H: quinone oxidoreductase 1 NQO1* 2 genotype (P187S) is a strong prognostic and predictive factor in breast cancer. Nature genetics 2008; 40(7):844-53.
The Iranian Journal of Obstetrics, Gynecology and Infertility
Volume 25, Issue 10
December 2022
Pages 10-20

Files

Share

How to cite

Statistics